Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 1;13(1):2419686. doi: 10.1080/2162402X.2024.2419686

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 7. — Expression of B7-H3 in renal cancer cells affects 2D and 3D viability.

a) B7-H3 protein expression in renal cancer cell lines. Immunoblot of cell lysates from 786-O, A498 and Caki-1 human renal cancer cells and RC-124 benign human renal cells. b) B7-H3 protein expression in renal cancer cell lines upon B7-H3 knockdown. Immunoblot of cell lysates from Caki-1 and 786-O human renal cancer cells upon B7-H3 knockdown using two different siRNAs. Quantifications of B7-H3/GAPDH are shown in the bottom panel. c, d) Viability of renal cancer cells upon knockdown of B7-H3. c) 2D and d) 3D-spheroid cell viability of Caki-1 and 786-O renal cancer cells upon knockdown of B7-H3 and upon treatment with tyrosine kinase inhibitor axitinib. e) B7-H3 protein expression in 786-O renal cancer cell line upon B7-H3 CRISPR/Cas knockout. Immunoblot of cell lysates from 786-O human renal cancer cells upon scramble (SCR) or B7-H3 CRISPR/Cas knockout (B7-H3 KO). Quantifications of B7-H3/GAPDH are shown in the bottom panel. f) Viability of renal cancer cells upon CRISPR/Cas knockout of B7-H3. 2D (upper panel) and 3D-spheroid (bottom panel) cell viability of 786-O renal cancer cells upon CRISPR/Cas knockout of B7-H3 and upon treatment with axitinib. Data are represented as the mean from at least two biological replicates, each one with at least three technical replicates.